Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factorsReportar como inadecuado




Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 17:16

Medical and radiation oncology

Abstract

BackgroundTo compare the efficacy of sorafenib and sunitinib with regard to overall survival OS and progression free survival PFS in Chinese patients with metastatic renal cell carcinoma mRCC.

MethodsA multicenter, retrospective study was performed to elucidate the relationship between clinical variables and prognosis comparing sorafenib and sunitinib as first-line treatment agents in Chinese patients with mRCC. Between September 2006 and December 2014, 845 patients received either sorafenib 400 mg bid; n = 483 or sunitinib 50 mg q.d; n = 362. The primary end point was OS and PFS.

ResultsThe percentage of patients with low and moderate risk according to Memorial Sloan-Kettering Cancer Centre MSKCC score was significantly higher in sunitinib group, and that with high risk was significantly higher in sorafenib group 15.1 vs. 5.2%; p < 0.001. Median OS was similar in sorafenib and sunitinib group 24 vs. 24 months; p = 0.298. Sorafenib group exhibited higher mPFS compared to sunitinib group 11.1 vs. 10.0 months; p = 0.028. Treatment sorafenib vs sunitinib, pathology, Eastern Cooperative Oncology Group ECOG performance status, MSKCC scores, Heng’s criteria of risk, and number of metastases were identified as significant predictors for OS and along with liver metastasis for PFS. Clinical outcomes in terms of mOS was significantly better with sorafenib in patients ≥65 years of age p = .041, ECOG 0 p = 0.0001, and median MSKCC risk score p = 0.008.

ConclusionsSorafenib and sunitinib are both effective in treating mRCC. However, sorafenib might be more effective in elderly patients ≥65 years and in patients with an ECOG status of 0, classified under MSKCC moderate risk.

KeywordsMetastatic renal cell carcinoma Sorafenib Sunitinib Prognosis Survival AbbreviationsAEAdverse effect

CTComputer tomography

DFSDisease free survival

ECOCGEastern cooperative oncology group performance status

mOSMedian overall survival

mPFSMedian progression free survival

mRCCMetastatic renal cell carcinoma

MRIMagnetic resonance imaging

MSKCCMemorial sloan-kettering cancer centre

ORRObjective response rate

OSOverall survival

PFSProgression free survival

PIPrescribing information

QoLQuality of life

RECISTResponse evaluation criteria in solid tumors

Hai-Liang Zhang and Xi-Nan Sheng are co-first authors.

Download fulltext PDF



Autor: Hai-Liang Zhang - Xi-Nan Sheng - Xue-Song Li - Hong-Kai Wang - Zhi-Hong Chi - Zhi-Song He - Ding-Wei Ye - Jun Guo

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados